Background: We investigate if switching from a ritonavir-boosted lopinavir (LPV/r)based to an efavirenz-based antiretroviral therapy (ART) regimen is associated with beneficial bone development.
Introduction
Advances in antiretroviral therapy (ART) have altered the disease course for the estimated 2.6 million children in the world living with HIV [1] . For those with perinatally acquired HIV, initiation of ART early in life has resulted in declines in mortality and survival well into adulthood [24] . Developing management approaches that optimize long-term outcomes for those with perinatally acquired HIV has emerged as an important area of clinical and public health research.
Among HIV-infected adults, the incidence of a number of chronic conditions, such as cardiovascular disease and osteoporosis, is increased [5] . The increased risk of osteoporosis and bone fractures in HIV-infected adults compared with the general population [6, 7] is likely because of multiple factors, including effects of HIV-1 viral proteins, inflammatory cytokines, and ARTon bone cells and bone turnover [8] [9] [10] [11] [12] [13] . Lower bone mass accrual is also reported in HIV-infected children and adolescents [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . While manifest later in life, osteoporosis has its origins in patterns of bone growth and turnover in childhood and adolescence when 85-90% of adult peak bone mass is attained [25] . Impaired skeletal growth during these critical periods may compromise bone microarchitecture and peak bone mass that are important determinants of bone strength and fracture risk in later life [26] [27] [28] . Few prior studies conducted in children, however, reflect current standards of care that emphasize initiation of ART early in life regardless of clinical or immunologic status. In addition, little is known about bone development among HIV-infected children in sub-Saharan Africa where more than 90% of HIV-infected youths live [1] .
Ritonavir-boosted lopinavir (LPV/r) is recommended by the WHO and widely used as part of the first-line regimen for HIV-infected children. Although ART regimens containing LPV/r are potent inhibitors of HIV replication and provide a high genetic barrier to emergence of drug resistance, there are a number of limitations for long-term use including poor palatability, dyslipidemias, and lipodystrophy [29] . Our group has demonstrated the safety and efficacy of pre-emptive switching to nonnucleoside reverse transcriptase inhibitors in children on LPV/r who have well suppressed virus [30] [31] [32] . Specifically, we recently reported the noninferiority in virological control through 48 weeks of switching to efavirenz-based therapy compared with remaining on LPV/r [32] . The objective of the current study was to first to compare bone mass of South African HIV-infected children initiated on ART early in life with an HIV-uninfected control group and second, as a followup of the children enrolled in the noninferiority trial, to investigate whether a switch from LPV/r to efavirenz for HIV-infected children well controlled on ART is associated with improved bone development.
Methods

Study population
We present a cross-sectional analysis of 219 HIV-infected and 219 HIV-uninfected children enrolled in the CHANGES Bone Study in Johannesburg, South Africa.
The 219 HIV-infected children were enrolled into the study after completion of a noninferiority randomized clinical trial evaluating the safety and efficacy of preemptive switching to efavirenz compared with remaining on LPV/r [32] . All children had been exposed to nevirapine used for prevention of mother-to-child transmission (PMTCT) and initiated on a protease inhibitor-based regimen, mostly LPV/r, at a mean age of 9 months. To be eligible for the clinical trial, children had to be virally suppressed on LPV/r at 3-5 years of age before being randomized to either remain on LPV/r or switch to efavirenz. A group of 219 healthy HIVuninfected children were recruited for the present study from among eligible siblings or household members of HIV-infected study patients or those attending the study site for routine outpatient health services. HIV-uninfected children with known chronic medical conditions, including known bone, renal, or liver disease, malabsorption syndrome, or inflammatory bowel disease, were excluded from enrollment.
Measurements and procedures
At the study visit, demographic data were collected, and all participants underwent physical examination to obtain anthropometric measures and to assess pubertal development. Weight was measured to the nearest 0.1 kg using a digital scale, and standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer. BMI was calculated as weight (kg) divided by height (m 2 ). Weight-for-age Z-scores (WAZ), heightfor-age Z-scores (HAZ), and BMI-for-age Z-scores (BAZ) were calculated using WHO standards [33] . Underweight was defined as WAZ less than À2 and stunted was defined as HAZ less than À2. Pubertal status was assessed and graded by trained study physicians according to the method of Tanner [34, 35] . Girls were staged using the highest score of either breast or pubic hair development. At the visit, blood was drawn and CD4 þ percentages and HIV RNA levels for HIV-infected children were measured (Roche COBAS TaqMan HIV-1 test; Indianapolis, IN, USA).
Bone area (cm 2 ), bone mineral content (BMC) (g), and areal bone mineral density (BMD) (g/cm 2 ) of the whole body (subtotal excluding the head) and lumbar spine (L1-4) were determined by dual-energy X-ray absorptiometry (DXA) using a Hologic Discovery Wi bone densitometer with Apex software version 3.4 (Hologic Inc, Bedford, Massachusetts, USA). Standard operational procedures for obtaining DXA images, data transfer, image reading, quality assurance, and data management were established involving the Department of Radiology of Rahima Moosa Mother and Child Hospital (Johannesburg, South Africa) and Image Reading Center (New York, New York, USA). All scans were analyzed by a single technician blinded to the HIV status and treatments of the participants. Lumbar spine scans performed in fast array mode were used for this analysis.
DXA provides a measure of areal BMD, not volumetric BMD, that systematically underestimates bone massfor-age in small-for-age children and the International Society for Clinical Densitometry recommends adjusting DXA results for short stature [36] ; therefore, we calculated whole-body and lumbar spine BMC Z-scores adjusted for sex, age, race, and height-age Z-score based on reference norms from the US Bone Mineral Density in Childhood Study [37] . This method accounts for considerable size deficits for children with perinatally acquired HIV-infection and correlates well with volumetric BMD determined by quantitative computed tomography [38, 39] .
The frequency and duration of physical activities and sedentary behaviors were obtained with a validated interviewer-administered recall questionnaire that detailed all physical activity and inactivity over the past 7 days [40, 41] . The number of minutes of vigorous physical activity per week was calculated as previously described, and the proportion of children meeting WHO recommendations for physical activity was determined [42, 43] . Dietary intake was collected by an intervieweradministered 24 h recall of the previous day's intake. Total calcium (mg) and vitamin D (IU) intake per day was calculated using FoodFinder3 software (South African Food Data Systems, South African Medical Research Council, Cape Town, South Africa) that includes the South African Food Composition Database [44] .
Signed informed consent was provided by each child's parent or guardian. Children provided assent if they were at least 7 years old and able to understand. The study was approved by the Institutional Review Boards of Columbia University (New York, New York, USA) and the University of the Witwatersrand (Johannesburg, South Africa).
Statistical analysis
We compared characteristics, as well as whole-body and lumbar spine BMC, BMD, and BMC Z-scores, between HIV-infected and HIV-uninfected children and HIVinfected children randomized to remain on LPV/r and HIV-infected children randomized to switch to efavirenz by intent-to-treat analysis. Linear regression was used to adjust comparisons of Z-scores between the HIV-infected and HIV-uninfected groups for physical activity and dietary vitamin D and calcium, as well to adjust comparisons of Z-scores between children on LPV/r and children on efavirenz for physical activity and dietary vitamin D and calcium, as well as viral load and CD4 þ percentage and current nucleoside reverse transcriptase inhibitor (NRTI) backbone (abacavir þ lamivudine, stavudine þ lamivudine, or zidovudine þ lamivudine). All analyses were stratified by sex. Sensitivity analyses were conducted excluding the 12 children who were Tanner Stage 2 at the time of assessment. We also repeated all analyses as-treated, comparing bone outcomes for the HIV-infected children based on their current treatment groups (LPV/r vs. efavirenz). In addition, current duration on efavirenz as both a categorical (currently not on efavirenz, on efavirenz 0-24 months, on efavirenz 24 months or greater) and as a continuous variable was assessed. Where applicable, a chi-squared or Fisher's exact test was used to compare proportions, a t test was used to compare means, and a Wilcoxon rank sum test was used to compare medians. All P values are two-tailed and P values less than 0.05 were considered statistically significant. All statistical calculations were performed using SAS version 9.4 (Cary, North Carolina, USA).
Results
Demographic and anthropometric characteristics of the 219 HIV-infected children (49% man) and 219 HIVuninfected children (55% man) are presented in Table 1 . HIV-infected children were younger than controls (mean 6.4 vs. 7.0 years). As expected, WAZ was lower in the HIV-infected group, and 11% of the children were underweight compared with 3% in the HIV-uninfected group. Similarly, HAZ was lower in the HIV-infected group, and 28% of the children were stunted compared with 9% in the HIV-uninfected group. HIV-infected children engaged in approximately 2 h fewer of vigorous activity compared with HIV-uninfected children. Mean reported dietary intake of vitamin D (IU/day), and calcium (mg/day) was low in both groups.
Characteristics of the HIV-infected children grouped according to original randomization are presented in Table 2 . The children were enrolled into the present study 1-4 years (mean 2.1 years) after randomization in the clinical trial. All HIV-infected children were on a three drug ARTregimen. In addition to either LPV/r or efavirenz, all children were receiving two NRTIs. All were receiving lamivudine and either abacavir, zidovudine, or stavudine. None had any past or current use of tenofovir. None were receiving corticosteroids or antiepileptic medications. The mean (SD) duration on treatment for HIV-infected children was 5.7 (1.1) years (range 2.8-8.7). At the time of evaluation, 93.6% of children had an HIV-1 RNA quantity less than 400 copies/ml and a mean (SD) CD4 þ percentage 37.3 (7.1).
DXA results for HIV-infected and uninfected children are presented in Table 3 . HIV-infected children had significantly lower whole-body mean BMC (415 vs. 490 g, P < 0.0001) and BMD (0.51 vs. 0.55 g/cm 2 , P < 0.001) compared with the HIV-uninfected group. The BMC Z-score was 0.15 lower in the HIV-infected group compared with the HIV-uninfected group (À0.95 vs. À0.80, P ¼ 0.046). The mean lumbar spine BMC and BMD were also significantly lower in the HIV-infected groups (14.4 vs. 16.1 g, P < 0.0001 and 0.46 vs. 0.49 g/cm 2 , P < 0.0001, respectively), but no differences in lumbar spine BMC Z-score were observed. Differences in BMC and BMC Z-score at the whole body and lumbar spine were similar when we excluded the children who were Tanner Stage 2 from the analysis.
Children randomized to switch to efavirenz had a higher whole-body mean BMC (425 vs. 406 g, P ¼ 0.14) and BMD (0.52 vs. 0.50 g/cm 2 , P ¼ 0.016) compared with children randomized to remain on LPV/r. The mean lumbar spine BMC and BMD were also higher for children in the efavirenz vs. LPV/r group ( Whole-body and lumbar spine BMC Z-score differences between the LPV/r and efavirenz groups were similar after further adjustment for current NRTI backbone.
Additional analyses were performed stratified by sex. HIV-infected boys had lower whole-body BMC Z-score (À0.84 vs. À0.61, P ¼ 0.027) compared with HIVuninfected boys, but lumbar spine BMC Z-scores were not significantly different (À0.12 vs. À0.19, P ¼ 0.53). Whole-body BMC Z-scores were significantly lower in boys on LPV/r compared with boys on efavirenz (À1.02 vs. À0.67, P ¼ 0.03). Lumbar spine BMC Z-score was lower in boys on LPV/r compared with boys on efavirenz albeit NS (À0.23 vs. À0.01, P ¼ 0.15). No statistically significant differences were observed between HIV-infected girls and HIV-uninfected girls in whole-body BMC Z-score (À1.05 vs. À1.02, P ¼ 0.79) or lumbar spine BMC Z-score (À0.33 vs. À0.47, P ¼ 0.26). Girls on LPV/r had lower whole-body BMC Z-score (À1.37 vs. À0.69, P < 0.001) and lumbar spine BMC Z-score compared with girls on efavirenz (À0.64 vs. 0.03, P ¼ 0.0002).
The treatment regimen differences were similar between the intent-to-treat analysis reported above and in astreated analyses. Mean whole-body BMC Z-score of HIV-infected children currently on LPV/r, on efavirenz for 0-24 months, and on efavirenz for 24 months or greater are presented in Fig. 1 . There was a trend toward a greater mean whole-body BMC Z-score with increased duration on efavirenz (P < 0.0001), although there was no significant difference in whole-body BMC Z-score between children on efavirenz for 0-24 months and 24 months or greater. In an additional regression analysis treating current time on efavirenz as a continuous variable, for every 1 month increase in current duration on efavirenz use, whole-body BMC Z-score increased by 0.02 (P ¼ 0.0002). those switched to an efavirenz-containing regimen. To our knowledge, this is the first assessment of bone mass in a population of HIV-infected children living in sub-Saharan Africa, the region where more than 90% of HIV-infected children reside [1] .
Discussion
The finding that bone mass is better among those switched from an LPV/r-based regimen to an efavirenzbased regimen suggests that some of the reduction in attained BMC observed in HIV-infected children compared with uninfected children may be related to LPV/r treatment. Lower bone mass associated with LPV/r has been previously reported [14, 23] . In addition, studies conducted in HIV-infected adults report bone loss in association with many but not all protease inhibitors. A meta-analysis of cross-sectional studies by Brown and Qaqish [6] found an odds ratio for osteoporosis of 1.57 (95% CI 1.05-2.34) in HIV-infected persons treated with protease inhibitors compared with those on nonprotease inhibitor-containing ART regimens. The putative mechanisms for disruption of bone homeostasis by protease inhibitors are through direct toxicity to bone cells or bone-cell precursors but may vary by specific drug agents [45] . In-vitro and in-vivo studies have demonstrated that a number of protease inhibitor agents (including ritonavir) inhibit osteoclastogenesis by impairing RANKL-induced signaling [11, 46] . Increased differentiation of peripheral blood mononuclear cells into osteoclasts by upregulation of growth factors and suppression of antagonist transcripts in vitro is also reported with ritonavir [47] [48] [49] . Other potential pathways involve drug-induced reductions in mesenchymal stem-cell differentiation to osteoblasts, as well as alterations in osteoblast gene expression and decreased bone formation [9, 50] . Protease inhibitors may also inhibit conversion of 25-hydroxyvitamin D to the bioactive metabolite 1,25-dihydroxyvitamin D by suppression of 25-hydroxylase and 1a-hydroxylase and thus impair bone formation via disruption of calcium homeostasis [51] .
LPV/r, when used in combination with other agents, is a potent inhibitor of HIV replication and is widely used in young children. It was recommended initially as first-line ART for children because drugs used for PMTCT select non-NRTI-resistant virus in the majority of infants with vertically-acquired HIV [52] . Furthermore, LPV/r was shown in randomized trials to have superior virological efficacy among both PMTCT-exposed and unexposed infants and young children [53] . For these reasons, LPV/r is recommended as part of first-line ART for infants and young children (<3 years) by the WHO [54] . However, LPV/r has a number of limitations of long-term use including poor palatability, dyslipidemia, and lipodystrophy [29] . The greater BMC among children who switched to efavirenz from LPV/r we observed may provide additional rationale for limiting LPV/r exposure once viral suppression has been achieved [30, 31, 55] .
In addition to ART, HIV-1 viral proteins may also have direct and indirect adverse effects on bone cells. In-vitro studies demonstrate that exposure of osteoblast precursors to HIV proteins results in decreased osteogenesis [13] , and exposure of osteoclast precursors to HIV proteins results increased osteoclast activation and differentiation [8] .
HIV viral proteins have also been shown to induce T-cell activation and elaboration of TNFa and RANKL, which induce osteoclastic bone resorption [8] . In our study, bone mass was reduced in HIV-infected children despite viral suppression. Residual low grade viral replication and immune activation are known to persist despite effective ART [56, 57] ; therefore, the decreased BMD accrual in our HIV-infected children may be due to the effects of ARTexposure, as well as the direct effects of HIV viral replication and indirect effects of immune activation on bone cells.
Multiple studies report reduced bone mass accrual among children and adolescents with HIV compared with HIV-uninfected children [14, 21, 58] . These studies have assessed bone mass accrual largely by DXA. Whether these reductions in bone mass largely measured by DXA are solely due to smaller body size has not been established satisfactorily due mainly to inconsistencies in adjusting for smaller body size and selection of comparison group or reference norms. In this study, we observed differences between HIV-infected and HIV-uninfected children in BMC Z-scores adjusted for age, sex, race, and HAZ, which account for body size difference, suggesting that decrements in bone mass are out of proportion to reductions in size. Neither do the decreases in bone accrual appear to be due to dietary intake of vitamin D and calcium or physical activity differences.
Although DXA does not distinguish between cortical (or compact) and trabecular bone, we found the differences between HIV-infected and HIV-uninfected patients more consistently in whole-body BMC and BMD rather than lumbar spine similar to a report by Jacobson et al. [59] . Skeletal bone mass comprises 80% cortical bone that provides much of the mechanical strength and 20% trabecular bone, whereas the spine is approximately 20% cortical bone and 80% trabecular bone [60] , and the distal ends of long bones (e.g. distal radius) also comprise largely trabecular bone. Although caution is warranted in interpretation, these findings suggest that during childhood, cortical bone accrual may be more vulnerable to effects of LPV/r. Studies that apply imaging methods such as quantitative CT, which provide measures of cortical and trabecular bone, are needed to better understand and the importance of these findings to mechanical bone properties and strength and potential for increasing fracture risk.
In this sample, the HIV-infected boys appear to have worse measures of bone mass compared with HIVuninfected boys. This pattern of sex differences in bone outcomes with more unfavorable findings among boys has been reported by others, especially after puberty. Jacobson et al. [59] in a US study of 48 perinatally HIVinfected boys and girls reported sex differences in postpubertal bone measures, but not at earlier stages of biologic maturation. Postpubertal HIV-infected boys had lower adjusted whole-body BMC, as well as adjusted whole-body and lumbar spine BMD than controls.
Another study conducted in Brazil found no sex differences in patterns of bone measures between HIV-infected boys and girls [61] . Determining whether the sex differences we observed persist throughout the period of skeletal maturation is an important area of future research.
The inclusion of an HIV-uninfected comparison group is a strength. We chose to use population norms drawn from a large study in the USA as there are none available for children in this age group in South Africa or another African country which would have been preferable. Thus, our main outcomes cannot be used for identifying individual study patients with low bone or estimating the prevalence of low bone mass (e.g. Z-score <À2) as there are important population differences in bone mass characteristics [37] . In addition, although we were able to measure other potential confounders including physical activity, and dietary vitamin D and calcium, these were based on self-report and are patient to nondifferential misclassification. Although we were unable to assess independent effects of NRTI on bone, exposure to stavudine vs. abacavir vs. zidovudine did not attenuate the differences between LPV/r and efavirenz. Finally, we are limited by the cross-sectional nature of the study, as we did not have a measure of bone mass available at randomization in the trial.
Bone mass accrual during childhood and adolescence is a major determinant of adult peak bone mass, which in turn is an important determinant of osteoporosis later in life and lifetime fracture risk. Maximizing bone accumulation during childhood may have an immediate benefit by reducing fractures in adolescence [62] ; however, potential deferred benefits of decreasing osteoporosis and fracture in older age are far more important [63] . Mathematical models indicate that relatively small increases (10%) in peak bone mass acquisition in healthy women could delay the onset of osteoporosis by as much as 13 years [64] , underscoring the importance of identifying strategies to optimize bone acquisition in HIV.
In conclusion, accrued bone mass is positively associated with switching to efavirenz-based ART compared with remaining on LPV/r, and switching may help children achieve better peak bone mass. Use of 'bone friendly' drugs may be beneficial for bone health in children with HIV.
